Match the Antibody
Identify species, isotype, subclass, Fc design, light-chain family, fragment format, and binding accessibility.
Select an antibody capture ligand by the part of the molecule that is available to bind. Protein A and Protein G primarily support Fc-mediated capture of many IgG molecules, while Protein L recognizes compatible κ light-chain variable regions and can capture Fc-free fragments. This hub connects binding biology with resin design, elution, impurity control, and reuse.
Choose a Starting Point
Develop the Cycle
Set load, residence time, wash, elution, neutralization, regeneration, and pool criteria.
Protect Product Quality
Control low-pH exposure, aggregation, clipping, nonspecific binding, and hold-time risk.
Control the Lifecycle
Monitor capacity, pressure, impurity clearance, ligand leakage, cleaning, storage, and reuse.
Protein A, Protein G, and Protein L at a Glance
| Ligand | Main antibody interaction | Common strengths | Critical limitations |
|---|---|---|---|
| Protein A | Primarily the Fc region of many IgG molecules; some Protein A domains can also interact with certain VH3-family variable regions | Established capture platform for many human and recombinant IgG/Fc-containing molecules; high selectivity and process scalability | Binding varies by species, subclass, Fc engineering, and molecule; elution is often acidic; leached ligand requires control |
| Protein G | Fc region at a site that overlaps but is not identical to Protein A binding | Broad IgG species/subclass coverage; useful when Protein A binding is weak, including many mouse IgG1 and human IgG3 applications | Affinity still varies; native Protein G contains albumin-binding regions, so purification ligands should be evaluated by construct |
| Protein L | Selected framework regions of compatible κ light-chain variable domains | Captures intact antibodies and Fc-free formats such as Fab, scFv, and some domain antibodies when the light chain is compatible | Does not bind λ light chains and does not recognize all κ subfamilies equally; compatibility must be demonstrated |
Do not select from an affinity chart alone. Species and subclass tables are useful screening tools, but variable-region sequence, Fc mutations, glycosylation, aggregation, feed composition, ligand construct, and immobilization can change observed binding.
A Five-Step Antibody Capture Development Path
Define the moleculeFormat, species, isotype, subclass, Fc sequence, κ/λ light chain, fragments, conjugation, and stability.
Map the feedAntibody titer, cells and particles, host proteins, DNA, aggregates, lipids, pH, conductivity, and viscosity.
Screen bindingCompare ligand and resin candidates at relevant load and residence time with target-specific analytics.
Optimize the cycleDevelop equilibration, load, wash, elution, neutralization, regeneration, cleaning, and storage.
Confirm lifecycleChallenge variability and track capacity, recovery, quality, leakage, pressure, bioburden, and cycle history.
Capture Questions by Antibody Format
| Antibody format | First capture question | Useful next experiment |
|---|---|---|
| Conventional human IgG | Does Protein A provide sufficient capacity and acceptable elution for this specific molecule? | Breakthrough and elution-pH screen with recovery, monomer, aggregate, and host-protein analysis |
| Mouse or rat monoclonal IgG | Which ligand binds the exact species and subclass most strongly under acceptable conditions? | Parallel Protein A and Protein G microscale capture using the same feed |
| Human IgG3 or weak Protein A binder | Can Protein G improve capture without compromising recovery or impurity clearance? | Protein G binding/elution screen followed by packed-bed confirmation |
| Fab or scFv without Fc | Is the κ variable domain compatible with Protein L? | Small-scale binding test plus nonbinding control; evaluate alternative affinity or physicochemical capture if incompatible |
| Fc-fusion or engineered Fc molecule | Have Fc mutations or steric features altered ligand accessibility or elution behavior? | Functional DBC and recovery study using the actual construct |
| Polyclonal antibody pool | Will heterogeneous subclasses and variable regions produce competitive binding or biased recovery? | Compare input and eluate subclass/functional distributions at increasing load |
Core Guides in This Topic
Each article addresses a different decision so that the series functions as a connected technical resource rather than eight versions of the same resin overview.
Protein A vs Protein G vs Protein L: Antibody Resin Selection
Compare binding site, molecule format, species/subclass coverage, fragment capture, elution, and development risk.
Protein A Chromatography: Binding, Washing and Elution
Develop the complete capture cycle from feed conditioning and load through wash design, elution, neutralization, and regeneration.
How to Choose an Antibody Purification Resin
Move beyond ligand name to compare matrix, pores, particles, dynamic capacity, pressure, chemical stability, format, and supply.
Protein G Purification for Antibody Species and Subclasses
Use species/subclass information as a testable starting point and design confirmation experiments for animal and recombinant antibodies.
Protein L Purification: Applications and Binding Limitations
Understand κ-variable-domain recognition, fragment capture, λ-chain exclusion, sequence dependence, and practical workflow design.
Low-pH Antibody Elution: Recovery and Aggregation Control
Separate elution requirements from low-pH hold requirements and control exposure time, neutralization, concentration, and pool handling.
Removing Leached Protein A After Antibody Capture
Prevent, measure, and clear residual ligand using capture-cycle control and orthogonal polishing informed by its product association.
Antibody Capture Resin Reuse: What to Evaluate
Design a resin-lifetime study around cleaning effectiveness, functional performance, product quality, microbial control, and economics.
Evidence Needed for a Defensible Capture Decision
| Decision area | Laboratory evidence | Additional process evidence |
|---|---|---|
| Binding | Recovery and functional capacity with the actual antibody and feed | DBC across residence times, load challenge, feed-lot variability |
| Wash | Target loss and impurity removal by fraction | Robustness ranges, buffer preparation, hold and transition effects |
| Elution | Yield, concentration, monomer/aggregate, activity, and pool pH | Scale mixing, neutralization kinetics, pooling criteria, low-pH hold integration |
| Impurities | Host proteins, DNA, aggregates, and ligand leakage as relevant | Clearance across orthogonal steps and method qualification |
| Reuse | Capacity, recovery, pressure, and visual/packing condition | Cleaning validation, microbial control, cycle bracketing, cross-contamination assessment |
Resources, Products, and Development Support
Need to select or troubleshoot an antibody capture step?
Share the antibody format, host species, subclass, light chain, feed, scale, required purity, and current bottleneck. Our team can review suitable products or develop a target-specific purification study.
For research or industrial raw materials only. Suitability must be evaluated for the intended molecule, process, and quality requirements.
Selected References
- Zarrineh M, et al. Mechanism of antibodies purification by Protein A. Anal Biochem. 2020;609:113909. doi:10.1016/j.ab.2020.113909.
- Page M, Thorpe R. Protein A and Protein G purification of antibodies. Methods Mol Biol. 2019;1904:11–24.
- Carta G, Jungbauer A. Protein Chromatography: Process Development and Scale-Up. 2nd ed. 2020.
